| Sep 25 |
Cassava's Simufilam: Safe On The Outside, Scrambled On The Inside
|
| Sep 25 |
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
|
| Sep 25 |
Why I'm Avoiding Cassava Stock For Now
|
| Sep 24 |
Cassava Sciences' on-going late stage trials for Alzheimer's treatment gets DSMB nod
|
| Sep 24 |
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
|
| Sep 18 |
Cassava Sciences inks consulting pact with ex-CEO Remi Barbier
|
| Sep 9 |
Cassava Sciences’ Richard Barry to take helm as permanent CEO
|
| Sep 9 |
Cassava Sciences Names Rick Barry as Chief Executive Officer
|
| Sep 3 |
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
|
| Aug 20 |
Cassava Sciences: Volatility Provides Trading Opportunities
|
